Clinical trials: Neoadjuvant Treatment
Rectal Cancer
The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
Comparative analysis of the clinical efficacy between primary Total Mesorectal Excision (TME) surgery and neoadjuvant chemotherapy combined with TME surgery for low-risk locally advanced rectal cancer.
- Trial name
- TaLaR-02 (NCT05984485)
- Testing
- neoadjuvant chemotherapy plus total mesorectal excision, total mesorectal excision
- Where
- 6 sites in China
- Volunteers
- 766 people
- Sponsor
- Sun Yat-sen University
Chemotherapy Effect
Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China
Neoadjuvant chemotherapy for advanced-stage gastric cancer is justified by various studies, however, there was not any large scale randomized controlled trial (RCT) to support it until German oncologist introduced a novel…
- Trial name
- NCT03646591
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Leukemia
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer treated with cytarabine in the laboratory may help doctors learn more about the effects of cytarabine on cells.
- Trial name
- NCT01338974
- Testing
- gene expression analysis, proteomic profiling, flow cytometry
- Volunteers
- 290 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer
This study will investigate whether cyclooxygenase inhibition with celecoxib will add any benefit to preoperative chemotherapy alone for breast cancer patients.
- Trial name
- NCT00135018
- Testing
- celecoxib and chemotherapy
- Where
- Hong Kong
- Sponsor
- Organisation for Oncology and Translational Research
HR+/HER2- Breast Cancer, Breast Neoplasms
Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
This study is a single-center, prospective, open-label exploratory clinical study to assess the efficacy and safety of kumorixilib combined with capecitabine and letrozole as neoadjuvant therapy in patients with HR+/HER2- stage…
- Trial name
- NCT07691333
- Testing
- Kumorixilib 180mg, Capecitabine 500mg, Letrozole 2.5mg
- Where
- 3 sites in China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Rectal Cancer
Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During Chemoradiotherapy
This project first retrospectively analyzes the intestinal dose indicators related to the concurrent radiotherapy and chemotherapy of rectal cancer and gastrointestinal toxicity, and the pelvic dose indicators related to…
- Trial name
- NCT05688033
- Testing
- dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Gastric Cancer
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (serplulimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer…
- Trial name
- NCT06128252
- Testing
- Taurine, Serplulimab, XELOX regimen
- Where
- 15 sites in China
- Volunteers
- 96 people
- Sponsor
- Tang-Du Hospital
Nasopharyngeal Carcinoma
A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma
The standard treatment strategy of locally advanced nasopharyngeal carcinoma (NPC) nowadays is concurrent chemoradiation (CCRT) based on intensity-modulated radiation therapy (IMRT).
- Trial name
- NCT02512315
- Testing
- Docetaxel (DOC), Cisplatin (DDP), Concurrent chemoradiation (CCRT)
- Where
- 4 sites in China
- Volunteers
- 192 people
- Sponsor
- Sun Yat-sen University
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma
This prospective, open-label, single-arm Phase 2 study is evaluating toripalimab plus axitinib as induction therapy for adults with newly diagnosed metastatic clear cell renal cell carcinoma whose primary kidney tumor remains in…
- Trial name
- TACTIC-RCC (NCT07776717)
- Testing
- Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy
- Volunteers
- 30 people
- Sponsor
- Fudan University
Rectal Cancer
Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery
Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment, will receive a preoperative…
- Trial name
- PIER (NCT03000374)
- Testing
- Panitumumab, 5Fluorouracil, Oxaliplatin
- Where
- 11 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Tumor Microenvironment, Lung Squamous Cell Carcinoma
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy
- Conditions
- Tumor Microenvironment, Lung Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06436040
- Testing
- Pathological response assessment
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tang-Du Hospital
Breast Cancer, Breast Biopsy
Vacuum Assisted Biopsy and Surgery Correlation in HER2 and TN Breast Cancer Subtypes MRI Responders After Neoadjuvant Therapy: BISUCO TRIAL
BACKGROUND AND CURRENT STATUS: Advancements in neoadjuvant systemic treatments (NST) for HER2 positive and triple-negative (TN) breast cancer (BC) subtypes have led to high rates of pathologic complete response (pCR), raising…
- Trial name
- BISUCO (NCT06371989)
- Testing
- Image guided vacuum assisted biopsy
- Where
- Spain
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario 12 de Octubre
Rectal Cancer
Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)
The goal of this clinical trial is to learn if neoadjuvant short-course radiation (SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 works to treat patients with locally advanced rectal cancer (LARC).
- Trial name
- NeoCaCRT-III (NCT06832917)
- Testing
- AK104 plus, Chemo only
- Volunteers
- 238 people
- Sponsor
- Wan He
Breast Cancer, HER2-positive Breast Cancer
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
To evaluate the efficacy and safety of the SHR6390 in combination with anastrozole, pyrotinib, and trastuzumab in patients with ER-positive, HER2-positive breast cancer in the neoadjuvant setting.
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, ER-positive Breast Cancer
- Trial name
- NCT04236310
- Testing
- SHR6390, Anastrozole, Pyrotinib
- Volunteers
- 37 people
- Sponsor
- Ruijin Hospital
Breast Cancer
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations
The purpose of this study is to compare the efficiency and safety between paclitaxel combined with epirubicin and vinorelbine combined with epirubicin when used in neoadjuvant chemotherapy for locally advanced (IIb-IIIc)…
- Trial name
- NCT02628613
- Testing
- Vinorelbine plus Epirubicin, Paclitaxel plus Epirubicin
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Fudan University
Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
This phase I trial studies the side effects and best dose of vaccine therapy given directly into the bladder in treating patients who are undergoing surgery to remove all or part of the bladder.
- Conditions
- Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma
- Trial name
- NCT00072137
- Testing
- Recombinant Fowlpox-TRICOM Vaccine, Recombinant Fowlpox GM-CSF Vaccine Adjuvant, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Soft Tissue Sarcoma
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma
Chemotherapy is controversial for soft tissue sarcoma that has not yet metastasized. Surgery and radiation are effective for local control, but there are no highly effective interventions to prevent metastatic spread of soft…
- Trial name
- NEXIS (NCT03116529)
- Testing
- Combination Radiation, Immunotherapy, Surgery
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Maryland, Baltimore
Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer
English Translation (Professional Medical Version) This study is a multicenter, prospective clinical trial designed to investigate the efficacy and safety of neoadjuvant therapy with trastuzumab plus pertuzumab combined with…
- Trial name
- NCT07589972
- Testing
- neoadjuvant therapy
- Volunteers
- 45 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Urothelial Carcinoma
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
SURE-01 is a neoadjuvant phase 2, open-label, non-randomized, singlecohort study in patients with urothelial carcinoma of the bladder. Patients will be consecutively enrolled and treated.
- Trial name
- NCT05226117
- Testing
- Sacituzumab govitecan
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- IRCCS San Raffaele
Rectal Neoplasms
Fish Oil Supplement in Rectal Cancer
Neoadjuvant treatment with radiotherapy (RDT) and chemotherapy (CT) are the treatment of choice for rectal adenocarcinomas in stages II and III. This results currently in pathologic complete response in 10% to 30% of cases.
- Trial name
- NCT02534389
- Testing
- omega-3 fish oil
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.